Seres Therapeutics Inc

NASDAQ:MCRB   3:59:58 PM EDT
3.41
+0.07 (+2.10%)
Earnings Announcements

Seres Therapeutics Reports First Quarter 2022 Results

Published: 05/04/2022 12:58 GMT
Seres Therapeutics Inc (MCRB) - Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates.
FDA Agreement Obtained for Rolling Ser-109 Biologics License Application (bla) Plan; Filing Completion on Track for Mid-2022.
Ended Q1 of 2022 With Approximately $248.0 Million in Cash, Cash Equivalents and Investments.
Qtrly Loss per Share $0.61.
Q1 Earnings per Share View $-0.52 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $4.55 Million
Adjusted EPS is expected to be -$0.60

Next Quarter Revenue Guidance is expected to be $6.98 Million
Next Quarter EPS Guidance is expected to be -$0.55

More details on our Analysts Page.